Company* |
Funding |
Amount |
Type | Details (Date) |
Active Biotech |
Swedish Governmental Agency for Innovation Systems |
SEK5 |
Funding support |
Funds will support preclinical work on drugs to treat autoimmune/inflammatory diseases (11/21) |
Addrenex |
The North Carolina Biotechnology Center |
$0.15 |
Research loan |
Loan will support the development of Clonicel, an oral, ex- tended-release formulation for symptoms associated with excessive adrenaline secretion (1/8) |
Adenosine |
National Institute of Allergy and Infectious Diseases |
$0.86 |
Phase I STTR Advanced Technology grant |
Funds will support research on the use of apadenoson, a selective A2A agonist, for the treatment of sepsis (10/26) |
Adenosine |
National Institute of Allergy and Infectious Diseases |
$0.76 |
Phase II SBIR grant |
Funds will support work to identify an A2BR antagonist as a therapeutic candidate for treating asthma (10/26) |
Adenosine |
National Institute of Allergy and Infectious Diseases |
$0.14 |
Phase I STTR grant |
Funds will support research on the use of agents that activate adenosine A2A receptor subtypes for treating arthritis (10/26) |
Adenosine |
National Institute of Allergy and Infectious Diseases |
$0.13 |
Phase I STTRgrant |
Funds will support preclinical research on the use of agents that activate adenosine A2A receptor subtypes for treating Gram-positive sepsis (10/26) |
Advanced Cell |
National Institutes of Health |
$0.204 |
Research grant |
The grant will fund the company's embryonic stem cell biology, phage display, phage targeting technology and gene discovery (1/16) |
Advanced Cell |
California Institute for Regenerative Medicine |
$2.52 |
Four-year grant |
The grant will fund work done at the University of California using Advanced Cell's human embryonic stem cells derived from its ACTcellerate technology (3/20) |
Affinium |
Defense Threat Reduction Agency (unit of the U.S. Department of Defense) |
$4.8 |
Two-year research contract |
The two-year contract will fund preclinical studies of selected compounds from Affinium's fatty- cid biosynthesis inhibitor portfolio (1/4) |
Allon |
Michael J. Fox Foundation for Parkinson's Research |
ND |
Grant |
Funding will go toward evaluating Allon's lead drug, AL-108, inpreclinical models of Parkinson's (1/24) |
ALSP Inc.* |
National Institute of Aging |
$0.296 |
R21 grant |
For development of an Alzheimer's disease compound (2/14) |
Althea |
National Human Genome Research Institute |
ND |
SBIR grant |
To explore the potential for practical high-throughput and low-cost gene expression analysis; the grant proposes the development of gene expression profiling methods that make use of Althea's multiplexed PCR methods and the IsoCyte high-throughput laser scanner platform from Blushift Biotechnologies Inc. (2/1) |
Apogenix GmbH* |
German Federal Ministry of Education and Research |
£0.9 (US$1.74) |
Research grant |
The funds will be used to study Apogenix' lead drug, APG101, for the treatment of spinal cord injuries; the research will be carried out in collaboration with the German Cancer Research Center (3/12) |
Argos |
National Institutes of Health |
$21.3 |
Contract award |
The five-year project involves development of personalized, RNA-loaded dendritic cell immunotherapy products for HIV; Argos is working with several institutions on the program, and has rights to resulting products (10/27) |
|
Ark Therapeutics Group plc (UK;PK:ARKTF) |
European Commission |
€2.5 (US$3.3) |
Grant |
To fund a consortium of commercial and academic collaborators to carry out further research into the use of insect-derived baculoviruses as vectors for gene therapy (2/7)** |
AVI |
U.S. Department of Defense |
$28 |
Contract award |
Two-year contract from the Defense Threat Reduction Agency will fund development of antisense therapeutics to treat the effects of Ebola, Marburg and Junin hemorrhagic viruses (12/4) |
BioMedomics* |
The North Carolina Biotechnology Center |
$0.025 |
Research loan |
Loan will support diagnostics targeting point-of-care personalized genetic testing for specific disease markers (1/8) |
Bolder |
National Cancer Institute |
$0.776 |
Phase II SBIR grant |
Bolder can get up to $0.776M for preclinical studies of its long- acting VEGF inhibitor, which is being developed as a treatment for various cancers (11/10) |
Cambridge |
Bill & Melinda Gates Foundation |
N/A |
Grant |
Cambridge will formulate DNA vaccines that do not need to be refrigerated against malaria, tuberculosis and AIDS; the foundation is providing $10M over five years for the Grand Challenges in Global Health Initiative (1/24)** |
Ceragenix |
U.S. Department of Defense and the Department of Veterans Affairs |
$3.9 |
Grants |
University researchers received the grants to test Ceragenix's Cerashield to help find ways to reduce infections associated with artificial limbs (1/29) |
Cerus Corp. |
NIH's National institute of Allergy and Infectious Diseases; Bill & Melinda Gates Foundation |
ND |
Grants |
To develop prophylactic and therapeutic vaccines for hepatitis C virus and HIV based on the company's Listeria platform (3/5) |
Cilian AG* |
German Federal Ministry of Education and Research |
ND |
Grant |
To develop a low-cost expression system for the production of biopharmaceuticals (2/2) |
Crucell NV |
Supranational organization |
$20 |
Contract |
Crucell was awarded a $20M contract for 2007 to provide its Quinvaxem pediatric vaccine for Latin America; the deal is separate from a Dec. 1 $230M contract (12/8) |
Crucell NV |
Supranational organizations |
$230 |
Contracts |
Crucell was awarded three-year contracts to provide its Quinvaxem and Hepavax-Gene vaccines, which will be used in children's vaccination programs (12/1) |
Crucell NV |
European Union |
€2.4 (US$3.1) |
Grant |
Grant will advance the development of a two- component pediatric malaria vaccine (1/24) |
Devgen NV |
Flemish government |
€0.9 (US$1.2) |
Grant |
To develop new targets and therapeutic solutions for obesity (2/26) |
Diffusion |
Office of Naval Research |
$0.5 |
Grant |
To advance trans-sodium crocetinate into a Phase I trial; it is designed to treat hemorrhagic shock (2/2) |
EpiVax Inc.* |
National Institute of Neurological Disorders and Stroke |
$0.37 |
Innovative Research Grant |
To fund studies on reengineering botulinum toxin, a protein used for cosmetic purposes and for movement disorders (2/28) |
Galapagos NV |
European Union |
€$0.5 ($6.6) |
Grant |
Funds will support Galapagos unit BioFocus DPI's participation in PROLIGEN, a research consor- tium focused on regeneration of injured kidneys (12/4) |
ImQuest |
International Partnership for Microbicides |
ND |
Grant |
For the advanced preclinical evaluation of pyrimidinedione drugs as topical microbicides (3/1) |
Integrated |
U.S. Environmental Protection Agency |
ND |
Phase I SBIR grant |
Funds will be used to develop methods to improve the bioproduction of butanol, by rescuing the effect of solvent toxicity on the production microbes (3/13) |
Iomai Corp.(IOMI) |
U.S. Department of Health and Human Services |
$14.5 |
Contract |
Funds are for Iomai's dose-sparing skin patch, which would be used with any available vaccines against the avian H5N1 strain (1/17) |
Maas BioIAB |
Defense Threat Reduction Agency |
$0.117 |
Award |
For a project to investigate the neuroprotective properties of cyclosporin in models of chemical warfare agent exposure (2/5) |
Med BioGene |
National Research Council Canada Industrial Research Assistant Program |
C$0.307 (US$0.265) |
Grant |
To develop genetic biomarkers for cardiovascular disease (2/8) |
Molecular LogiX |
Houston Technology Center and Gulf Coast Regional Center of Innovation and Commercialization for the Texas Emerging Technology Fund |
$0.79 |
Grant |
Funds will support development of a first-in- class cancer treat-ment using its Pan-HER anti-cancer ligand, a genetically engineered version of a naturally occurring growth hormone that blocks the cell receptor necessary for tumor cell growth (3/20) |
Nanogen Inc. |
Centers for Disease Control and Prevention |
$4.5 |
Contract |
Funds will support first phases of a project to develop a multi-analyte point-of-care diagnostic assay for Influenza (12/4) |
Neurocrine |
Michael J. Fox Foundation for Parkinson's Research |
ND |
Grant |
Grant to study the potential neuroprotective effects of adenosine A2A receptor antagonists in models of Parkinson's disease (1/24) |
Omeros Corp.* |
Stanley Medical Research Institute |
$9 |
Equity and grant funding |
Funds are to further develop Omeros' schizophrenia drug, covering costs through the completion of Phase I trials (1/10) |
Pipex |
National Institutes of Health |
$0.306 |
Grant |
To support testing of the anti-copper drug candidate Coprexa in Alzheimer's disease (2/15) |
PLx Pharma Inc.* |
Houston Technology Center and Gulf Coast Regional Center of Innovation and Commercialization for the Texas Emerging Technology Fund |
$2 |
Grant |
Grant will help PLx develop safer and more effective formulations of nonsteroidal anti- inflammatory drugs using a platform technology licensed from the University of Texas Health Science Center (3/20) |
Pressure |
National Institutes of Health |
$0.15 |
SBIR grant |
Another six-month grant will be used to demonstrate the feasibility of using the company's Pressure Cycling Technology to develop an automated sample preparation procedure for the extraction and purification of nucleic acids from a variety of biological samples in a single processing step (3/9) |
Proneuron |
Michael J. Fox Foundation for Parkinson's Research |
$0.43 |
Grant |
Grant to examine PN277's ability to prevent degeneration of dopaminergic neurons and to reverse dopamine loss in relevant preclinical models (1/24) |
Rexahn |
Maryland Industrial Partnerships Program |
$0.2 |
Grant |
Rexahn received a $215,408 grant to pursue the development of water-soluble nano-polymers for targeted delivery of cancer drugs (3/6) |
Sanaria Inc.* |
National Institute of Allergy and Infectious Diseases |
$3.47 |
SBIR grants |
Two multiyear grants will enhance the development of its whole-parasite malaria vaccine; the first-year award is $1.21M (1/29) |
Sangamo |
Juvenile Diabetes Research Foundation |
$3 |
Funding support |
The JDRF will provide up to $3M to support Sangamo's Phase II trials of SB-509, a ZFP therapeutic for treating diabetic neuropathy (10/26) |
Sangamo |
Michael J. Fox Foundation for Parkinson's Research |
$0.95 |
Award |
Award will be paid over two years for work on a ZFP therapeutic (1/23) |
Semafore |
Multiple Myeloma Research Foundation |
$0.996 |
Grant |
Funds will support all patient- associated costs of Semafore's upcoming Phase I trial evaluating the p12K inhibitor SF1126 in multiple myeloma (12/5) |
Semafore |
Cancer Treatment Research Foundation |
$0.535 |
Grant |
Funds will support patient and manufacturing costs of a Phase I trial of SF1126 in advanced multiple myeloma patients (12/5) |
SIGA |
U.S. Air Force |
$1.4 |
Contract award |
Funding will support development of countermeasures against Dengue viruses and other water-related viral agents (11/10) |
SIGA |
U.S. Air Force |
$0.9 |
Contract award |
SIGA will support the USAF Special Operations Command's development of antiviral agents, focusing on orthopoxvirus targets that are distinct from the target of the smallpox agent SIGA-246 (11/10) |
Teotten |
The North Carolina Biotechnology Center |
$0.15 |
Research loan |
Loan will support the development of tests for hospital-acquired infections (1/8) |
ThromboGenics |
European Union |
€2 (US$2.6) |
Grant |
The EU approved a grant to the Vasoplus consortium, a development program for a new class of pro-angiogenesis agents; the companies are part of a group working to further develop placental growth factor and analogues of that pro-angiogenic cytokine for treating ischemic heart disease, peripheral arterial occlusive disease, tissue regeneration and wound healing (1/16) |
Transgene SA |
French Agency for Industrial Innovation |
€25 ($33) |
Grant |
Funds would support the firm's participation in the Advanced Diagnostics and New Therapeutic Approaches program focused on personalized medicine; European Commission approval of the grant was expected in 2Q:07 (11/27) |
Unigene |
National Institute for Diabetes and Digestive and Kidney Diseases |
$0.9 |
Phase II SBIR grant |
Funds will support the continuation of the company's discovery program for therapeutic peptide hormones; grant will be given over two years (2/15) |
XOMA Ltd. |
National Institute of Allergy and Infectious Diseases |
$28.1 |
Subcontract from SRI International Inc. |
XOMA will manufacture various monoclonal antibody therapeutic agents for the NIAID under the five-year award worth up to $28.1M (11/7) |
Zyomyx Inc.* |
Imperial College London |
ND |
Grant |
Zyomyx received a grant to work on the college's CD4 Initiative; it will work on a new treatment management tool in developing countries for counting CD4+ T lymphocytes in blood in HIV/ AIDS patients; Zyomyx is entitled to milestone-dependent payments over the next four years (3/8) |
Notes: | ||||
* Indicates a privately held company; ** Denotes the date the item ran in BioWorld International. | ||||
Currency conversions reflect values at the time of a deal's announcement. | ||||
SBIR = Small Business Innovation Research; STTR = Small Business Technology Transfer. | ||||
Unless otherwise indicated, symbols listed are on the Nasdaq market. | ||||
BR = Brussels Stock Exchange; CDNX = Canadian Venture Exchange; FSE = Frankfurt Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; SSE = Stockholm Stock Exchange; TSX = Toronto Stock Exchange. | ||||
